26 August 2026

Natco Pharma investment in eGenesis

This is a corporate investment news item that provides context on the emerging field of xenotransplantation and biotechnology, which is relevant to health and science syllabus themes but lacks the direct policy or national impact required for a higher rating.

Questions

1. Discuss the potential of xenotransplantation in addressing the critical shortage of human organs for medical procedures. What are the ethical and regulatory challenges associated with such biotechnological advancements? 150 words
   Attempt this — 150 words in 8 min

   0 / 150 words 8:00 Reset

Prelims

1. Which of the following best describes the core area of research for the biotechnology company eGenesis?

   1. A Production of affordable generic vaccines for developing nations
   2. B Genetically engineered, human-compatible organs for transplantation
   3. C Advancement of gene-editing techniques for agricultural crop resilience
   4. D Development of synthetic pharmaceutical drugs for chronic diseases